PedAM

Pediatric Disease Annotations & Medicines


	anuria

Disease ID	1363
Disease	anuria
Definition	Absence of urine formation. It is usually associated with complete bilateral ureteral (URETER) obstruction, complete lower urinary tract obstruction, or unilateral ureteral obstruction when a solitary kidney is present.
Synonym	[d]anuria [d]anuria (context-dependent category) [d]anuria (situation) absence of urine volume absent urine output anuria (finding) anuria [disease/finding] anurias passes no urine suppression of urinary secretion urinary output arrest of urine formation failure of
DOID	DOID:2983
UMLS	C0003460
MeSH	D001002
SNOMED-CT	SNOMEDCT_US_2016_09_01:2472002
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:12) C0035078 \| renal failure \| 15 C0022660 \| acute renal failure \| 9 C0079924 \| oligohydramnios \| 5 C0022661 \| chronic renal failure \| 2 C0017152 \| gastritis \| 1 C0020538 \| high blood pressure \| 1 C0020538 \| hypertension \| 1 C0034150 \| purpura \| 1 C0035078 \| kidney failure \| 1 C0041327 \| pulmonary tb \| 1 C0034152 \| henoch-schonlein purpura \| 1 C0022658 \| nephropathy \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:3) PLAU \| 5328 \| CTD_human AGT \| 183 \| CTD_human ALB \| 213 \| CTD_human
Inferring Gene	(Waiting for update.)
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:76) 340533 \| KIAA2022 \| DISEASES 28954 \| REM1 \| DISEASES 7380 \| UPK3A \| DISEASES 973 \| CD79A \| DISEASES 4353 \| MPO \| DISEASES 9450 \| LY86 \| DISEASES 5657 \| PRTN3 \| DISEASES 3024 \| HIST1H1A \| DISEASES 718 \| C3 \| DISEASES 55821 \| ALLC \| DISEASES 10343 \| PKDREJ \| DISEASES 1401 \| CRP \| DISEASES 1131 \| CHRM3 \| DISEASES 27130 \| INVS \| DISEASES 25939 \| SAMHD1 \| DISEASES 23523 \| CABIN1 \| DISEASES 56606 \| SLC2A9 \| DISEASES 11178 \| LZTS1 \| DISEASES 5286 \| PIK3C2A \| DISEASES 8128 \| ST8SIA2 \| DISEASES 5972 \| REN \| DISEASES 2796 \| GNRH1 \| DISEASES 3934 \| LCN2 \| DISEASES 6291 \| SAA4 \| DISEASES 5741 \| PTH \| DISEASES 8526 \| DGKE \| DISEASES 7547 \| ZIC3 \| DISEASES 1636 \| ACE \| DISEASES 3889 \| KRT83 \| DISEASES 3490 \| IGFBP7 \| DISEASES 213 \| ALB \| DISEASES 90678 \| LRSAM1 \| DISEASES 189 \| AGXT \| DISEASES 2147 \| F2 \| DISEASES 5340 \| PLG \| DISEASES 56776 \| FMN2 \| DISEASES 137814 \| NKX2-6 \| DISEASES 9622 \| KLK4 \| DISEASES 1237 \| CCR8 \| DISEASES 10215 \| OLIG2 \| DISEASES 342184 \| FMN1 \| DISEASES 2152 \| F3 \| DISEASES 5764 \| PTN \| DISEASES 3005 \| H1F0 \| DISEASES 9863 \| MAGI2 \| DISEASES 641 \| BLM \| DISEASES 23556 \| PIGN \| DISEASES 257194 \| NEGR1 \| DISEASES 7867 \| MAPKAPK3 \| DISEASES 4151 \| MB \| DISEASES 6238 \| RRBP1 \| DISEASES 10724 \| MGEA5 \| DISEASES 183 \| AGT \| DISEASES 10370 \| CITED2 \| DISEASES 462 \| SERPINC1 \| DISEASES 262 \| AMD1 \| DISEASES 959 \| CD40LG \| DISEASES 11093 \| ADAMTS13 \| DISEASES 229 \| ALDOB \| DISEASES 1471 \| CST3 \| DISEASES 8869 \| ST3GAL5 \| DISEASES 5420 \| PODXL \| DISEASES 3030 \| HADHA \| DISEASES 7436 \| VLDLR \| DISEASES 3652 \| IPP \| DISEASES 1363 \| CPE \| DISEASES 29072 \| SETD2 \| DISEASES 10640 \| EXOC5 \| DISEASES 3112 \| HLA-DOB \| DISEASES 23109 \| DDN \| DISEASES 3113 \| HLA-DPA1 \| DISEASES 1029 \| CDKN2A \| DISEASES 4700 \| NDUFA6 \| DISEASES 100423062 \| IGLL5 \| DISEASES 567 \| B2M \| DISEASES 102723508 \| KANTR \| DISEASES
Locus	(Waiting for update.)

Disease ID	1363
Disease	anuria
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:18) HP:0000083 \| Renal insufficiency \| 15 HP:0001919 \| Acute renal failure \| 11 HP:0001562 \| Oligohydramnios \| 5 HP:0002027 \| Abdominal pain \| 2 HP:0003774 \| End-stage renal failure \| 2 HP:0008682 \| Renal tubular necrosis \| 1 HP:0003256 \| Coagulopathy \| 1 HP:0000822 \| Hypertension \| 1 HP:0002015 \| Swallowing difficulty \| 1 HP:0012531 \| Pain \| 1 HP:0000979 \| Purpura \| 1 HP:0001260 \| Dysarthric speech \| 1 HP:0100806 \| Sepsis \| 1 HP:0030164 \| Jaw claudication \| 1 HP:0000967 \| Petechiae \| 1 HP:0000112 \| Nephropathy \| 1 HP:0002615 \| Low blood pressure \| 1 HP:0005263 \| Gastritis \| 1

Disease ID	1363
Disease	anuria
Manually Symptom	(Waiting for update.)
Text Mined Symptom	(Waiting for update.)

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:29)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0003460	acetaminophen	D000082	103-90-2	anuria	MESH:D001002	marker/mechanism	7634817
C0003460	ampicillin	D000667	69-53-4	anuria	MESH:D001002	marker/mechanism	1128370
C0003460	bleomycin	D001761	11056-06-7	anuria	MESH:D001002	marker/mechanism	9572663
C0003460	cerivastatin	C086276	-	anuria	MESH:D001002	marker/mechanism	11795020
C0003460	cimetidine	D002927	51481-61-9	anuria	MESH:D001002	therapeutic	552491
C0003460	colchicine	D003078	64-86-8	anuria	MESH:D001002	marker/mechanism	17497454
C0003460	cisplatin	D002945	15663-27-1	anuria	MESH:D001002	marker/mechanism	9572663
C0003460	diclofenac	D004008	15307-86-5	anuria	MESH:D001002	marker/mechanism	15752411
C0003460	diltiazem	D004110	42399-41-7	anuria	MESH:D001002	marker/mechanism	9207477
C0003460	enalapril	D004656	75847-73-3	anuria	MESH:D001002	marker/mechanism	7951836
C0003460	enflurane	D004737	13838-16-9	anuria	MESH:D001002	marker/mechanism	973714
C0003460	epirubicin	D015251	56420-45-2	anuria	MESH:D001002	marker/mechanism	9572663
C0003460	ethambutol	D004977	74-55-5	anuria	MESH:D001002	marker/mechanism	15102986
C0003460	folic acid	D005492	59-30-3	anuria	MESH:D001002	marker/mechanism	851170
C0003460	metaraminol	D008680	54-49-9	anuria	MESH:D001002	marker/mechanism	14122464
C0003460	ifosfamide	D007069	3778-73-2	anuria	MESH:D001002	marker/mechanism	2320800
C0003460	indinavir	D019469	150378-17-9	anuria	MESH:D001002	marker/mechanism	11096305
C0003460	indomethacin	D007213	53-86-1	anuria	MESH:D001002	marker/mechanism	1870807
C0003460	ivermectin	D007559	70288-86-7	anuria	MESH:D001002	marker/mechanism	8555762
C0003460	metformin	D008687	657-24-9	anuria	MESH:D001002	marker/mechanism	15752411
C0003460	methotrexate	D008727	1959/5/2	anuria	MESH:D001002	marker/mechanism	2918955
C0003460	mitomycin	D016685	1950/7/7	anuria	MESH:D001002	marker/mechanism	12813674
C0003460	morphine	D009020	57-27-2	anuria	MESH:D001002	marker/mechanism	8225663
C0003460	norepinephrine	D009638	51-41-2	anuria	MESH:D001002	marker/mechanism	2948068
C0003460	oxytetracycline	D010118	79-57-2	anuria	MESH:D001002	marker/mechanism	7364640
C0003460	phenindione	D010630	1983/12/5	anuria	MESH:D001002	marker/mechanism	4234096
C0003460	piroxicam	D010894	36322-90-4	anuria	MESH:D001002	marker/mechanism	4004367
C0003460	rifampin	D012293	13292-46-1	anuria	MESH:D001002	marker/mechanism	19376565
C0003460	sulfadiazine	D013411	68-35-9	anuria	MESH:D001002	marker/mechanism	4761062

FDA approved drug and dosage information(Total Drugs:4)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D001002	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D001002	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D001002	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D001002	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes

FDA labeling changes(Total Drugs:4)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D001002	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D001002	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D001002	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D001002	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE